Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
93 stopped studies mapped to Malignant Mesothelioma and descendants · 88% state a reason
Over the 93 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04031469 | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease | — | suspended | Jul 24, 2019 | ProgenaBiome | Administrative | Other (stated, no rule matched) |
| NCT05703854 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction… | Phase 1 / Phase 2 | suspended | Jan 30, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03075527 | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural… | Phase 2 | terminated | Mar 9, 2017 | Dana-Farber Cancer Institute | Criteria not met for second stage at time of interim analysis | Efficacy / futility |
| NCT04158141 | Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy… | Phase 3 | terminated | Nov 8, 2019 | NRG Oncology | Permanent Administrative Closure | Other (stated, no rule matched) |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Phase 1 | terminated | Oct 7, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Safety / toxicity |
| NCT03684486 | Rehabilitation by Effort for Patients With Advanced Bronchial Cancer(RehabKBP) | N/A | terminated | Sep 25, 2018 | University Hospital, Toulouse | recruitment difficulties | Enrollment / accrual |
| NCT01851395 | Rapid Autopsy and Procurement of Cancer Tissue | — | terminated | May 10, 2013 | National Cancer Institute (NCI) | PI departure. | Other (stated, no rule matched) |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06654050 | Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma | Phase 2 | withdrawn | Oct 23, 2024 | National Cancer Institute (NCI) | The study is being withdrawn due to the CRADA with the company not being finalized | Sponsor / business decision |
| NCT04166734 | Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant…(MESO-PRIME) | Phase 1 | terminated | Nov 18, 2019 | Royal Marsden NHS Foundation Trust | Study terminated due to slow recruitment and insufficient further funding. | Enrollment / accrual |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT02863055 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma(NEMO) | Phase 2 | terminated | Aug 11, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | lack of scientific relevance (change in the treatment landscape) and poor recruitment | Enrollment / accrual |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT02613299 | Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural… | — | terminated | Nov 24, 2015 | Mayo Clinic | slow accrual related to change in standard-of-care treatment | Enrollment / accrual |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT04214015 | A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma | — | withdrawn | Dec 30, 2019 | ProgenaBiome | Company focus shifted | Sponsor / business decision |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT02648763 | Staging Procedures to Diagnose Malignant Pleural Mesothelioma | — | terminated | Jan 7, 2016 | Mayo Clinic | due to low/slow accrual | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | Ikena Oncology | Sponsor strategic reasons | Sponsor / business decision |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT02748798 | Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI… | Early Phase 1 | terminated | Apr 22, 2016 | Thunder Bay Regional Health Research Institute | Funding is no longer available due to the failure to enroll the target number of participants… | Enrollment / accrual |
| NCT02613312 | Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified… | — | terminated | Nov 24, 2015 | Mayo Clinic | Practice change in what is considered standard of care | Other (stated, no rule matched) |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Sep 26, 2018 | Pfizer | The decision to stop enrollment was due to strategic considerations and not due to any specific… | Safety / toxicity |
| NCT03319537 | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | Phase 1 / Phase 2 | terminated | Oct 24, 2017 | Memorial Sloan Kettering Cancer Center | Sponsor terminated study agreement | Other (stated, no rule matched) |
| NCT03502746 | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | Phase 2 | terminated | Apr 19, 2018 | Arkadiusz Z. Dudek, MD | IRB Study Closure | Other (stated, no rule matched) |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in… | Phase 1 / Phase 2 | terminated | Jul 12, 2013 | Kyowa Kirin Korea Co., Ltd. | lack of efficacy | Efficacy / futility |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant… | Phase 2 | terminated | Dec 6, 2013 | Verastem, Inc. | Company decided to discontinue trial to focus on development program next steps | Sponsor / business decision |
| NCT03393858 | Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma | Phase 1 / Phase 2 | terminated | Jan 9, 2018 | Capital Medical University | The number of enrolled cases is insufficient | Enrollment / accrual |
| NCT04840615 | Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant… | Phase 1 | terminated | Apr 12, 2021 | National Cancer Institute (NCI) | Study was closed early due to slow accrual. | Enrollment / accrual |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT02688166 | Cardiac MRI Biomarker Testing (GCC 1618) | — | terminated | Feb 23, 2016 | University of Maryland, Baltimore | Unable to meet accrual goal | Enrollment / accrual |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing…(NAC-PNP) | N/A | terminated | Mar 18, 2008 | Rijnstate Hospital | Unable to recruit enough patients | Enrollment / accrual |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer… | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by IRB on 3/28/22 | Other (stated, no rule matched) |
| NCT02385812 | Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma | Phase 2 | terminated | Mar 11, 2015 | University of Calgary | Low enrollment through COVID pandemic | COVID-19 / pandemic |
| NCT03655821 | Dose Individualization of Pemetrexed - IMPROVE-II(IMPROVE-II) | Phase 4 | terminated | Aug 31, 2018 | Radboud University Medical Center | 81 patients included, difficult inclusion and full inclusion would not change the results | Other (stated, no rule matched) |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell… | Phase 1 / Phase 2 | terminated | Aug 9, 2016 | National Cancer Institute (NCI) | Slow/Insufficient accrual | Enrollment / accrual |
| NCT02838745 | Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With… | Phase 1 | terminated | Jul 20, 2016 | Baylor College of Medicine | Change in research plan. | Other (stated, no rule matched) |
| NCT02464904 | Intrapleural Cryotherapy for Malignant Pleural Mesothelioma | N/A | terminated | Jun 8, 2015 | Mayo Clinic | Difficulty enrolling patients due to enrollment criteria. | Enrollment / accrual |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT03644550 | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | Phase 2 | terminated | Aug 23, 2018 | National Cancer Institute (NCI) | Due to the Food and Drug Administration's recent approval of Nivolumab plus Ipilimumab as first… | Investigator |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung… | Phase 1 / Phase 2 | terminated | Apr 3, 2015 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT04429204 | Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma | N/A | withdrawn | Jun 12, 2020 | Jonsson Comprehensive Cancer Center | The study was not opened | Other (stated, no rule matched) |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | Phase 2 | withdrawn | Dec 26, 2018 | Health Pharma Professional Research | Publication of study results of ICI use in MPM as first line therapy | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials